摘要
目的观察罗格列酮和二甲双胍联合氯米芬治疗肥胖型多囊卵巢综合征患者的内分泌改善及生殖功能的临床疗效。方法50例肥胖型PCOS患者分别给予罗格列酮4mg/d和二甲双胍1500mg/d联合氯米芬100mg/d,治疗3个月,比较治疗前后体重指数、内分泌参数、腰臀比和Hom a IR的变化。结果用罗格列酮治疗后排卵率为88%,周期排卵率为64.29%,优势卵泡平均个数为1.8±0.8个,妊娠率为56%,而用二甲双胍治疗后分别为72%、54.84%、1.1±0.6个、48%。两者治疗后能使LH、LH/FSH、T的血清浓度明显下降,SHBG的浓度明显上升,Hom a IR明显改善。结论罗格列酮和二甲双胍联合氯米芬治疗肥胖型多囊卵巢综合征疗效可靠。二甲双胍有降低体重作用、价格便宜,适用于肥胖型P-COS伴胰岛素抵抗不严重者;罗格列酮在胰岛素增敏作用优于二甲双胍,适用于胰岛素抵抗较严重的PCOS患者。
Objective： To investigate and compare the treatment effect of mefformin versus rosiglitazone on the obese type of PCOS. Methods ： 50 PCOS patients were randomly divided into two groups ： treat group with rosiglitazone combined with clomiphene and control group with mefformin combined with clomiphene. The therapeutic effect, chang of body mass index （BMI）, serum insulin, endocrinic function, oral glucloe tolerance test before and after treatment were analyzed in two groups. Results： The ovulation in treated group and in control group were 88%, 72% ; pregnancy rate were 56%, 48% respectively. There was significant decrease in the level of luteinizing hormone and testosterone and Homa IR between two groups after treatment. Concluion ： Rosiglitazone and mefformin can be effectively used to treat obese type of PCOS, especially for patients resistant to clomiphene. In cases with PCOS mefformin treatment influences better hyperandrogenemia, while rosiglitazone affects more pronouncedly insulin resistance and hyperinsulinemia.
出处
《中国优生与遗传杂志》
2006年第8期92-94,共3页
Chinese Journal of Birth Health & Heredity
关键词
二甲双胍
罗格列酮
多囊卵巢综合征
治疗
Obese type of polycystic ovary syndome
Mefformin versus rosiglitazone
Treatment
